Pharmaco - Today Stories

Galt Pharmaceuticals®, a pharmaceutical company committed to enhancing the quality of life of patients with products that meet unmet clinical needs, has introduced a 4-day work week for its employees. In a LinkedIn post, CEO and Co-Founder Barry Patel said, “We are not big pharma and are actually looking to disrupt the inefficient big pharma model. We know we can’t always offer the big pharma perks, but we can offer work-life balance and a family-first culture.” About Galt Pharmaceuticals® Galt Pharmaceuticals® has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve. Galt is the first and only company to cr…

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully dilute…

Alzheimer’s Research UK has been selected as the official 2021 charity partner of Hertfordshire-based company, Innovative Trials.  The company, which specialises in clinical trial patient recruitment and community engagement, is aiming to raise at least £5,000 for the charity over the next 12 months. The funds raised will support groundbreaking dementia research for a world free from the fear, harm, and heartbreak of dementia. In the UK, almost one million people are thought to be living with dementia and this is expected to rise to two million by 2050. Alzheimer’s Research UK is the UK’s leading dementia research charity committed to developing life-changing treatments and cures - a mission shared by Innovative Trials. Kate Shaw, founder and CEO of Innovative Trials, said: “Dementia is a…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on June 11, 2021, drug product manufacture of the Moderna COVID-19 vaccine at the site in France has now begun. “We are proud to be working with Recipharm to build industrial production capacity in France in support of Europe’s vaccination campaign,” said Stephane Bancel, Chief Executive Officer of Moderna. “France is at the heart of European innovation in healthcare and will play an important role in Moderna’s strategic growth plan.” “Our c…

Publication comes alongside new ABPI Principles to help companies operate to high ethical standards The Association of the British Pharmaceutical Industry (ABPI) 2021 Code of Practice comes into force from 1 July, alongside new ABPI Principles to help companies operate to high ethical standards.   The ABPI Code of Practice is the industry’s commitment to operate in a professional, ethical, and transparent manner, for the benefit of patients and the public. It is independently administered by the Prescription Medicines Code of Practice Authority (PMCPA). The 2021 Code has been updated to make the Code easier for companies to use in their day-to-day activities, to reflect changes in the environment companies operate in and to reflect updates to the European Code.  Some new elements increase…

Approximately €400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation Focus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet need Expected minimum of six clinical candidates by 2025 PARIS – June 29, 2021 - Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l’Etoile, Lyon (France). …

Ten leading German companies form this newly created Quantum Technology and Application Consortium Together, the members want to explore industrial applications for quantum computing Quantum computing has also great potential for pharmaceutical research and development Today, Boehringer Ingelheim joined the Quantum Technology and Application Consortium (QUTAC) as a founding member. This consortium unites ten of the leading German companies from the fields of chemistry and pharmaceuticals as well as from the insurance business and the automotive industry. Their aim is to take quantum computing to the level of large-scale industrial application. In doing so, the founding members want to make a significant contribution to advance this technology in the German and European market. “As part o…

Lifebit’s deep learning, Natural Language Processing and Artificial Intelligence platform automatically detects and tracks global infectious disease outbreaks using real-world evidence The captured insights can accelerate detection of the latest outbreaks including transboundary diseases and emerging pathogens Boehringer Ingelheim, a global leader in animal health, announces the beginning of a long-term partnership with Lifebit Biotech to utilize Artificial Intelligence (AI) for the detection and early-reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources. Utilizing the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow R&D efforts to be prioritized…

Leeds, UK, April 19, 2021 – 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces a collaboration with Parkinson’s UK, a non-profit organization focused on advancing the understanding of Parkinson’s disease and improving treatments, to establish a Patient Advisory Board. The Patient Advisory Board (PAB) will be comprised of people living with Parkinson’s. Supported by Parkinson’s UK, the PAB will provide valuable patient-centric perspective to 4D pharma as it continues to advance novel Live Biotherapeutics into the clinic to treat neurodegenerative conditions such as Parkinson’s. The PAB will also focus on raising awareness of the issues people wit…

Sanofi will invest €400 million over five years to create a unique vaccine production site in Singapore, pushing the boundaries of operations through cutting edge manufacturing and digital technologies. The new site will provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia, and quickly respond to future pandemic risks. The Singapore site will complement Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines production in Asia. PARIS – April 12, 2021 - Sanofi today announced a €400 million investment over five years to create a unique vaccine production center in Singapore, pushing the boundaries of operations through cutting edge manufacturing and digital technologies. In pa…

Sanofi announced today the successful completion of its acquisition of Kymab Group Ltd., adding KY1005 to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. The acquisition continues to build on Sanofi’s leading presence in immunology aligned with the company’s strategy to pursue best-in-class treatments in defined areas. Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase1/2 development as monotherapy and in combination with an anti-PD-L1. About SanofiSanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffe…

Sanofi announces investment of more than €600 million to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States and Europe In partnership with the Governments of Canada and Ontario, and the City of Toronto, the new facility will also enhance influenza pandemic preparedness efforts Fluzone® High-Dose Quadrivalent influenza vaccine has four times more antigen than standard-dose vaccine and is specifically designed to provide superior protection against influenza for older adultsi Sanofi today announced an investment of more than €600 million in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi’…

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments. Cognate BioServices is a premier, cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies, as well as for production of plasmid DNA and other inputs in the CDMO value chain. The acquisition establishes Charles River as a premier scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through CGMP production. The strategic benefits of the transaction include: p…

BIOGGIO, SWITZERLAND – March 29, 2021 – The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets give KD Pharma access to new complementary technologies that will allow the company to further expand its pharmaceutical contract manufacturing (“CDMO”) business. In addition, KD Pharma has strengthened its CDMO team by hiring several key personnel from the former Rohner team. “KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said Oscar Groet, CEO of the KD Pharma Group. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs” Groet continued, “this is a natural fit with our strategy to…

ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project. Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the proprietary, well-proven AGE1.CR.pIX® suspension cell line and its high performance cell culture medium, for the propagation of Nobelpharma’s virus strain. Now, ProBioGen applies state-of-the-art technologies and a deep expertise to perform the upstream and downstream process development for Nobelpharma's highly relevant vaccine for large scale manufacturing. The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents. It has a…

Merck Sharp & Dohme to participate in previously announced private placement Gross proceeds of Merger and private placement total approximately $39.8 million Leeds, UK – 22 March 2021 - 4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020 (the "Merger"), has now become effective. 4D pharma’s existing Board of Directors and management team will continue to lead the combined company. 4D will continue its operations in the discovery and development of Live Biotherapeutic products. The cash of $14.8 million hel…

Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company. Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and Gilde Healthcare. Additional investors in this round include Novartis Venture Fund, and Eli Lilly and Company, joining existing investor BioMotiv and founding investor Advent Life Sciences. The proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform. Amphista’s CEO Nicola Thompson said, “This financing round, led by…

Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections Basel, 15 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) today announced that they have entered i…

PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has completed the merger of Archemin BV to the PharmaLex Group Established in 1999, Archemin is a well-established pharmaceutical consultancy based in Mechelen, Belgium. Headed by its founder Ludwig Everaert, and supported by Anne Peeters, Operations Manager, their multidisciplinary team of 16+ experts provide services to both domestic and international clients. The merger complements our existing services by adding pharmacovigilance, quality management, medical information and market access consulting, allowing us to both increase our pool of expertise as well as our presence in the region. To build on our regional setting, Archemin will be a pivotal member of our France B…

- Acquisition Expands Takeda’s Immuno-Oncology Portfolio With Two Development Candidates and Maverick’s Conditionally Active Bispecific T-cell Engagers COBRA™ Platform, Specifically Designed to Target Solid Tumors - Maverick’s Lead Candidate TAK-186 (Formerly MVC-101), a Conditionally Active T-cell Engager, is First in its Class to Enter the Clinic With Recent Phase 1/2 Study Initiation - Multi-year, “Build to Buy” Collaboration Culminates in Takeda’s Exercise of Its Right to Acquire Maverick for up to $525 Million in Upfront and Potential Milestone Payments Subject to Certain Adjustments Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering condit…